Comparison

FABP4 Antibody

Item no. E90232
Manufacturer Enogene
Amount 100 ul
Quantity options 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 200 ul 100 ul 100 ul 50 ul 100 ul
Category
Type Antibody
Applications WB, IHC
Specific against Human (Homo sapiens), Mouse (Murine, Mus musculus), Rat (Rattus norvegicus)
Host Rabbit
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias FABP4 , aP2, ALBP, Fatty acid binding protein 4, AFABP, A FABP
Available
Manufacturer - Conjugate / Tag
This antibody is also available with the following conjugates:
AF350, AF405L, AF405M, AF405S, AF488, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF635, AF647, AF680, AF700, AF750, AF790, APC, AP, Biotin, Cy3, Cy5.5, Cy5, Cy7, FITC, HRP, PE, Magnetic beads (1 um, 2.8 um, 3 um, 4.5 um, 5 um, 10 um, 15 um, 20 um, 30 um, or different size option)
Please contact sales@hoelzel.de for pricing and availability.
Storage Conditions
Store at -20C or -80oC. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Molecular Weight
15kDa
Immunogen
Recombinant proteinof human FABP4
Purification
Affinity purification
Research Area
Autophagy antibody, Cancer, Cardiovascular, Cell Biology, Epigenetics and Nuclear Signaling, Developmental Biologys, Immunology, Drug Discovery Products, Metabolism, Neuroscience, Signal Transduction, Stem Cells
Background
Fatty acid binding proteins (FABPs) bind to fatty acids and other lipids to function as cytoplasmic lipid chaperones (1). They participate in the transport of fatty acids and other lipids to various cellular pathways (2). The predominant fatty acid binding protein found in adipocytes is FABP4, also called adipocyte fatty acid binding protein or aP2. FABP4 is also expressed in macrophages (3). FABP4 knockout mice fed a high-fat and high-calorie diet become obese but develop neither insulin resistance nor diabetes, suggesting that this protein might be a link between obesity and insulin resistance and diabetes (4). Mice deficient in both FABP4 and ApoE show protection against atherosclerosis when compared with mice deficient only in ApoE (3). Mice carrying a FABP4 genetic variant exhibit both reduced FABP4 expression and a reduced potential for developing type 2 diabetes and coronary heart disease. A related study in humans indicated a similar pattern, suggesting that FABP4 may be a potential therapeutic target in the treatment of these disorders (1).
CiteID
EN0124920

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ul
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close